Company: CI
Filing Date: 2025-09-04
Form Type: 424B5
Source: 0001140361-25-033868
Chunk: 10

Company: Cigna Group
Filing Date: 2025-09-04
Form: 424B5
Chunk 10
---
 of Control Offer”) occur with respect to Notes of any series, in which case, unless we have exercised our right to redeem such Notes as described under “Description of the Notes—Optional Redemption,” we will be required to make an offer to repurchase all of the Notes of such series, at a price equal to 101% of the principal amount of the 5-Year Notes, the 7-Year Notes, the 10-Year Notes or the 30-Year Notes, as applicable, plus any accrued and unpaid interest to, but excluding, the date of repurchase. See “Description of the Notes—Change of Control Offer.”**

#### Covenants
The Indenture (as defined herein) for the Notes contains limitations on liens on common stock of our Designated Subsidiaries (as defined in the Indenture) and limits our ability to consolidate with or merge with or into any other person (other than in a merger or consolidation in which we are the surviving person) or sell our property or assets as, or substantially as, an entirety to any person. These covenants are subject to important qualifications and limitations. See “Description of Debt Securities—Limitations on Liens on Common Stock of Designated Subsidiaries” and “Description of Debt Securities—Consolidation, Merger and Sale of Assets” in the accompanying prospectus.

#### Minimum Denominations
**The Notes will be issued and may be transferred only in minimum denominations of $2,000 and multiples of $1,000 in excess thereof.

Material United States Federal Income Tax Consequences

For a summary of certain United States federal income tax consequences of the purchase, ownership and disposition of the Notes, see “Material United States Federal Income Tax Consequences.”**

#### Risk Factors
For a discussion of factors you should carefully consider before deciding to purchase the Notes, see “Cautionary Note Regarding Forward-Looking Statements and Risk Factors” in this prospectus supplement and the “Risk Factors” discussed in our Annual Report on Form 10-K for the year ended December 31, 2024, incorporated by reference in this prospectus supplement and the accompanying prospectus.

<div align='center'>S-3</div>

#### TABLE OF CONTENTS

#### Conflicts of Interest
As described under “Use of Proceeds,” we intend to use a portion of the net proceeds from this offering to fund repayment of the Term Loan Facility. Certain of the underwriters or their affiliates are lenders under the Term Loan Facility. As